Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Closed 10-15 16:00:00 EDT

0.5000

+0.0298

+6.34%

盘后0.5000

+0.00000.00%

19:59 EDT

High0.5099	Low0.4379	Vol5.35M
Open0.4881	D1 Closing0.4702	Amplitude15.31%
Mkt Cap121.50M	Tradable Cap99.00M	Total Shares243.00M
T/O2.62M	T/O Rate2.70%	Tradable Shares198.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.5,"timestamp":1792094400000,"preClose":0.4702,"halted":0,"volume":5349576,"hourTrading":{"tag":"盘后","latestPrice":0.5,"preClose":0.5,"latestTime":"19:59 EDT","volume":33421,"amount":16525.8076,"timestamp":1792108769787,"change":0,"changeRate":0,"amplitude":0.026},"delay":0,"changeRate":0.06337728626116544,"floatShares":198000000,"shares":243000000,"eps":-0.747935,"marketStatus":"Closed","change":0.0298,"latestTime":"10-15 16:00:00 EDT","open":0.4881,"high":0.5099,"low":0.4379,"amount":2621584.21985808,"amplitude":0.153126,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.747935,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792137600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.4702,"preHourTrading":{"tag":"盘前","latestPrice":0.4824,"preClose":0.4702,"latestTime":"09:27 EDT","volume":80912,"amount":39028.49062112,"timestamp":1792070837453,"change":0.0122,"changeRate":0.025946,"amplitude":0.079115},"postHourTrading":{"tag":"盘后","latestPrice":0.5,"preClose":0.5,"latestTime":"19:59 EDT","volume":33421,"amount":16525.8076,"timestamp":1792108769787,"change":0,"changeRate":0,"amplitude":0.026},"volumeRatio":1.168516,"impliedVol":1.4398,"impliedVolPercentile":0.4104},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"2674854851","title":"Press Release: Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674854851","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674854851?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:30","pubTimestamp":1791549000,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA(TM) (bevacizumab-vik","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","AMUU","CHPS","LU1861558580.USD","SMH","AMD","AMDY","TEK","LU1064131342.USD","USXF","WISE","WUGI","SMHX","AMDC","CHAT","IETC","SOXY","AMDS","BK4007","LENZ","DAMD","ILDR","BAI","AMYY","AMDU","CNAV","AMDG","XNTK","TTEQ","LEGR","ARTY","SAMD0main","AIS","TM","SOXX","TRFK","FAI","FTXL","R","GAMR","QQQA","AIQ","AMDD","AMDL","03160","LU0174119429.USD","LU0823421333.USD","PSI","AMDW","LU1923623000.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673105192","title":"Outlook Therapeutics Names Kevin Lundquist CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673105192","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673105192?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:20","pubTimestamp":1791292819,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics names Kevin Lundquist CFOOutlook Therapeutics appointed Kevin Lundquist as chief financial officer as it shifts to a commercial-stage launch of LYTENAVA.Disclaimer:This news brief","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL3p409g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","BK4139","OTLK","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4585","BK4112","IE00BQXX3C00.GBP","BCDF","LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673519460","title":"Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2673519460","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673519460?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:20","pubTimestamp":1791292800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUAC6KQYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672875083","title":"Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA","url":"https://stock-news.laohu8.com/highlight/detail?id=2672875083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672875083?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:10","pubTimestamp":1790860239,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it has submitted an application to the Centers for Medicare & Medicaid Services, CMS, requesting a perma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-submits-hcpcs-level-ii-application-to-cms-for-j-code-for-lytenava-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-submits-hcpcs-level-ii-application-to-cms-for-j-code-for-lytenava-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK","BK4139","LNGR","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672946757","title":"Outlook Therapeutics - on Track for U.S. Launch of Lytenava Before Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672946757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672946757?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:01","pubTimestamp":1790859683,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0RG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672075792","title":"Outlook Therapeutics Submits Hcpcs Level Ii Application to CMS for Permanent J-Code for Lytenava™ (Bevacizumab-Vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672075792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672075792?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:01","pubTimestamp":1790859683,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0RG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782247","title":"Outlook Therapeutics Risks NASDAQ Delisting After 30-Day Sub-$1 Bid-Price Stretch","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782247","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782247?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:32","pubTimestamp":1790800360,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics risks Nasdaq delisting after 30-day sub-$1 bid-price stretchOutlook Therapeutics received a Nasdaq notice for failing the $1.00 minimum bid price rule, following 30 straight busin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8xRG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670620256","title":"Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences up 156%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670620256","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670620256?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:11","pubTimestamp":1790608260,"startTime":"0","endTime":"0","summary":"Shares of Kodiak Sciences more than doubled Monday after two experimental eye drugs succeeded in a late-stage trial, positioning the biopharmaceutical company to get its first product to market.Kodiak","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IBB","LU2023250504.SGD","LU2106854487.HKD","LU0109394709.USD","LU1917777945.USD","LU0823416689.USD","BK4505","LU0114720955.EUR","LU0289739699.SGD","LU2468319806.SGD","LU2362540622.SGD","LU2237438978.USD","IBBQ","LU2362541513.USD","BK4585","LU0058720904.USD","BK4139","LU0882574055.USD","LU2362541273.HKD","LU1974910355.USD","OTLK","REGN","TBXU","KOD","BBH","LU0053666078.USD","LU0889565916.HKD","LU0823434583.USD","LU0320765992.SGD","LU0823434740.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596987","title":"Outlook Therapeutics Wins FDA Approval for Lytenava in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596987","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596987?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:10","pubTimestamp":1789045841,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics wins FDA approval for LYTENAVA in wet AMDOutlook Therapeutics secured FDA approval for LYTENAVA, an ophthalmic bevacizumab formulation to treat wet age-related macular degeneratio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL5mc0dZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","BCDF","BK4588","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","BK4585","OTLK","NDAQ","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666880599","title":"Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666880599","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666880599?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:10","pubTimestamp":1789045800,"startTime":"0","endTime":"0","summary":"Access the segmenthere ISELIN, N.J., Sept.  10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTE","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359613/0/en/outlook-therapeutics-ceo-bob-jahr-discusses-fda-approval-and-commercial-opportunity-for-lytenava-in-virtual-investor-ceo-connect-segment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849050","title":"Outlook Therapeutics CFO Kevin Michael Lundquist Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849050","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849050?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:31","pubTimestamp":1788381093,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics CFO Kevin Michael Lundquist files initial beneficial ownership statementOutlook Therapeutics CFO Kevin Michael Lundquist filed an initial Form 3 on Sept. 2, dated Sept. 1.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8HJw5W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662038652","title":"Outlook Therapeutics Names Kevin Lundquist CFO, Replacing Lawrence Kenyon","url":"https://stock-news.laohu8.com/highlight/detail?id=2662038652","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662038652?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:07","pubTimestamp":1787861240,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics names Kevin Lundquist CFO, replacing Lawrence KenyonOutlook Therapeutics named Kevin Lundquist chief financial officer, effective Sept. 1, 2026.Lundquist previously served as CFO ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL5hCk65:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4082","IE00BGHQF748.EUR","CV","LU0314104364.USD","BCDF","BK4585","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210149790.SGD","OTLK","SG9999014021.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","BK4588","NDAQ","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662603834","title":"Outlook Therapeutics - Lawrence Kenyon to Step Down as CFO Effective September 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662603834","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662603834?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:05","pubTimestamp":1787861100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA6HF0N7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662038375","title":"Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as it Prepares for U.S. Commercial Launch of Lytenava™","url":"https://stock-news.laohu8.com/highlight/detail?id=2662038375","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662038375?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:05","pubTimestamp":1787861100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA6HF0N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700792","title":"Outlook Therapeutics Posts CEO Bob Jahr “Why Now” Investor Conference Webcast on Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700792","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700792?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:03","pubTimestamp":1787835791,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics posts CEO Bob Jahr “Why Now” investor conference webcast on demandOutlook Therapeutics published an on-demand video webcast of CEO Bob Jahr’s Virtual Investor “Why Now” conference","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL7W43HN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2W23.USD","OTLK","IE00B64PRP62.GBP","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","BK4588","LU2210150020.SGD","SG9999014005.SGD","BCDF","BK4585","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00BQXX3D17.EUR","BK4139","NDAQ","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660843471","title":"Outlook Therapeutics Delays Q2 Form 10-Q Filing After Finance Staff Turnover","url":"https://stock-news.laohu8.com/highlight/detail?id=2660843471","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660843471?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:06","pubTimestamp":1786997177,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics delays Q2 Form 10-Q filing after finance staff turnoverOutlook Therapeutics filed a Form 12b-25 to delay its quarterly Form 10-Q for the period ended June 30, 2026.Filing cited fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL4ptYQj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659120267","title":"Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear","url":"https://stock-news.laohu8.com/highlight/detail?id=2659120267","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659120267?lang=en_us&edition=fundamental","pubTime":"2026-08-15 13:26","pubTimestamp":1786771604,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics stock has had a very difficult five years, with the share price down about 98.3%, and the latest valuation checks currently do not flag the stock as a clear bargain despite this steep decline.\n\nOver the past five years, Outlook Therapeutics has declined around 98.3%, which means long term shareholders have seen most of their equity value eroded.\nThe recent approval and planned U.S. launch of LYTENAVA, supported by a US$55 million equity offering, can help fund growth but...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-otlk/outlook-therapeutics/news/outlook-therapeutics-otlk-stock-looks-fully-valued-while-boo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-otlk/outlook-therapeutics/news/outlook-therapeutics-otlk-stock-looks-fully-valued-while-boo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TACU","OTLK","TSPA","CDIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659122189","title":"Outlook Therapeutics CFO Lawrence Kenyon Acquires 101,010 Common Shares Valued at $99,999.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2659122189","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659122189?lang=en_us&edition=fundamental","pubTime":"2026-08-15 07:40","pubTimestamp":1786750807,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9Outlook Therapeutics CFO Lawrence A. Kenyon bought 101,010 common shares in an underwritten public offering p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2ShvCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics CFO Lawrence Kenyon Acquires 101,010 Common Shares Valued at $99,999.9","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144024","title":"Outlook Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144024","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144024?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:31","pubTimestamp":1786714271,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryOutlook Therapeutics IncOTLK.OQreported a quarterly adjusted loss of 9 cents per share for the quarter ended Ju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659413145","title":"Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2659413145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659413145?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:26","pubTimestamp":1786706773,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Q3 net loss narrows slightly as costs dropOverviewU.S. biopharmaceutical firm's fiscal Q3 net loss narrowedCompany advancing U.S. launch strategy for LYTENAVA, FDA-approved ophtha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4505","PLRX","BK4007","LENZ","BK4139","BK4539","KOD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.2031},{"period":"1month","weight":-0.2629},{"period":"3month","weight":-0.6779},{"period":"6month","weight":0.5207},{"period":"1year","weight":-0.6735},{"period":"ytd","weight":-0.7024}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0115},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.1621},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.075556},{"month":7,"riseRate":0.545455,"avgChangeRate":0.003223},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.194294},{"month":9,"riseRate":0.454545,"avgChangeRate":0.035752},{"month":10,"riseRate":0.454545,"avgChangeRate":0.144528},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}